Seattle Genetics is dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells.
From Promise to Therapy
Join The Seattle Genetics Team
We are a group of passionate innovators dedicated to positively impacting the lives of those living with cancer, and we're always looking to add to our team.
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) More
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer More
Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma More
Seattle Genetics At A Glance
|Global Headquarters||Bothell, WA|
|Number of Employees||1,000+|
|Clinical & preclinical pipeline programs||12+|
|ADCs in clinical trials using our technology||20+|
Primary Cutaneous Anaplastic Large Cell Lymphoma & Mycosis Fungoides represent the most common Cutaneous T-Cell #Lymphoma subtypes · 1 week ago